Japanese cabinet ministers endorsed on March 24 the appointment of Yoshihiro Yoneda, director of the National Institute of Biomedical Innovation, as head of a new institute to be created on April 1 through the merger of his organization, known as…
To read the full story
Related Article
- NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger
January 22, 2015
- Cabinet OKs Bill to Merge NIBIO, NIHN to Create New Institute
February 26, 2014
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





